Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events

INTRODUCTION: Afatinib is a first-line treatment option for patients with an advanced nonsmall cell lung cancer (NSCLC) expressing an epidermal growth factor receptor (EGFR) activating mutation. This study aimed to evaluate the association between early adverse events induced by afatinib and overall...

Descripción completa

Detalles Bibliográficos
Autores principales: Logan, Jessica M., Brooks, Doug A., Rowland, Andrew, Sorich, Michael J., Hopkins, Ashley M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225415/
https://www.ncbi.nlm.nih.gov/pubmed/34221011
http://dx.doi.org/10.1155/2021/2414897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225415/
https://www.ncbi.nlm.nih.gov/pubmed/34221011
http://dx.doi.org/10.1155/2021/2414897

Ejemplares similares